Case report: A case of severe capecitabine toxicity due to confirmed in trans compound heterozygosity of a common and rare DPYD variant
Variations in the activity of the enzyme dihydropyrimidine dehydrogenase (DPD) are associated with toxicity to fluoropyrimidine-containing chemotherapy. Testing of DPD deficiency either by targeted genotyping of the corresponding DPYD gene or by quantification of plasma concentration of uracil and d...
Saved in:
| Main Authors: | Amy de Haar-Holleman, Pieter-Jan Cortoos, Jelle Vlaeminck, Paulien Van Landuyt, Stephane Steurbaut, Freya Vaeyens, Vincent Haufroid |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1459565/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Implementation of DPYD testing in Bulgarian patients with cancer
by: Nelly Miteva-Marcheva, et al.
Published: (2024-12-01) -
Balance of care activity after EMA recommendation for DPYD gene testing in Galicia
by: Almudena Gil-Rodríguez, et al.
Published: (2025-03-01) -
DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews
by: Sara Otero-Torres, et al.
Published: (2025-05-01) -
DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol
by: Ana Hernández-Guío, et al.
Published: (2021-05-01) -
Study of polymorphisms of UGT1A1 and DPYD genes in chemotherapy for colorectal cancer
by: N. N. Timoshkina, et al.
Published: (2019-01-01)